5 Things You Need to Know About Bayesian Response-Adaptive Design

When multiple doses of a candidate drug are being evaluated in phase 2 studies, it can be a challenging, lengthy process to assess a dose-effect signal compared against a placebo. Alternative study designs, like the Bayesian response-adaptive design, are becoming increasingly popular in phase 2 studies where the goal is to identify the optimal dose(s) for phase 3 studies to confirm efficacy. For sponsors considering a Bayesian response-adaptive design, this guide provides the five things you need to know prior to developing your protocol.